V
Vincent Stroobant
Researcher at Ludwig Institute for Cancer Research
Publications - 6
Citations - 3154
Vincent Stroobant is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Antigen presentation & Antigen. The author has an hindex of 6, co-authored 6 publications receiving 2843 citations. Previous affiliations of Vincent Stroobant include Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
Catherine Uyttenhove,Luc Pilotte,Ivan Théate,Ivan Théate,Vincent Stroobant,Didier Colau,Nicolas Parmentier,Thierry Boon,Benoît Van den Eynde +8 more
TL;DR: It is shown that most human tumors constitutively express IDO, and that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice, suggesting that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.
Journal ArticleDOI
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte,Pierre Larrieu,Vincent Stroobant,Didier Colau,Eduard Dolusic,Raphaël Frédérick,Etienne De Plaen,Catherine Uyttenhove,Johan Wouters,Bernard Masereel,Benoît Van den Eynde +10 more
TL;DR: A TDO inhibitor was developed, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors and established proof-of-concept for the use of TDO inhibitors in cancer therapy.
Journal ArticleDOI
An antigen produced by splicing of noncontiguous peptides in the reverse order
Edus H. Warren,Edus H. Warren,Nathalie Vigneron,Nathalie Vigneron,Marc A. Gavin,Marc A. Gavin,Pierre Coulie,Vincent Stroobant,Vincent Stroobant,Alexandre Dalet,Alexandre Dalet,Scott S. Tykodi,Scott S. Tykodi,Suzanne M. Xuereb,Jeffrey K. Mito,Stanley R. Riddell,Stanley R. Riddell,Benoît Van den Eynde,Benoît Van den Eynde +18 more
TL;DR: A human minor histocompatibility antigen is described created by a polymorphism in the SP110 nuclear phosphoprotein gene that comprises two noncontiguous SP110 peptide segments spliced together in reverse order to that in which they occur in the predicted SP110 protein.
Journal ArticleDOI
Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
Eduard Dolusic,Pierre Larrieu,Laurence Moineaux,Vincent Stroobant,Luc Pilotte,Didier Colau,Lionel Pochet,Benoît Van den Eynde,Bernard Masereel,Johan Wouters,Raphaël Frédérick +10 more
TL;DR: This study led to the identification of a very promising compound displaying good TDO inhibition (K(i) = 5.5 μM), high selectivity, and good oral bioavailability, and 58 was chosen for preclinical evaluation.
Journal ArticleDOI
An antigenic peptide produced by reverse splicing and double asparagine deamidation
Alexandre Dalet,Paul F. Robbins,Vincent Stroobant,Nathalie Vigneron,Yong F. Li,Mona El-Gamil,Ken-ichi Hanada,James Chih-Hsin Yang,Steven A. Rosenberg,Benoît Van den Eynde +9 more
TL;DR: A class I-restricted peptide that combines several posttranslational modifications that is derived from tyrosinase and recognized by tumor-infiltrating lymphocytes isolated from a melanoma patient is described.